Medication info

Empagliflozin/Sitagliptin/Metformin Hydrochloride Controlled Release Tablet 5/50/750 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletSitagliptin Phosphate Hydrate›64.25mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›757.5mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Light purple, double-convex oval-shaped controlled release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501987 · Approved 2025.07.30

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily in the evening with a meal. If the metformin hydrochloride dose needs to be adjusted, increase the dose gradually. Patients taking the 25/100/1000 mg or 10/100/1000 mg extended-release tablet should take 1 tablet once daily. Patients taking the 12.5/50/750 mg or 5/50/750 mg extended-release tablet should take 2 tablets once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the initial dose of this medicine should provide empagliflozin 10 mg, sitagliptin 100 mg, and the patient's current metformin hydrochloride dose or a therapeutically equivalent dose. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be based on the previous doses of each component. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) falls below 45 ml/min or estimated glomerular filtration rate (eGFR) falls below 45 ml/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication helps improve blood sugar control when used in combination with diet and exercise for adults with type 2 diabetes. The three active ingredients, Empagliflozin, Sitagliptin, and Metformin, work together to effectively support blood sugar management. It can help stabilize blood sugar levels and may contribute to the prevention of complications. Therefore, this medication is a highly suitable treatment for blood sugar control in diabetic patients.

How to take

Adult dose

For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily in the evening with a meal. If the metformin hydrochloride dose needs to be adjusted, increase the dose gradually. Patients taking the 25/100/1000 mg or 10/100/1000 mg extended-release tablet should take 1 tablet once daily. Patients taking the 12.5/50/750 mg or 5/50/750 mg extended-release tablet should take 2 tablets once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the initial dose of this medicine should provide empagliflozin 10 mg, sitagliptin 100 mg, and the patient's current metformin hydrochloride dose or a therapeutically equivalent dose. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be based on the previous doses of each component. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) falls below 45 ml/min or estimated glomerular filtration rate (eGFR) falls below 45 ml/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication works by combining three ingredients to help control blood sugar. First, the Sitagliptin component may rarely cause serious allergic reactions. If symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, stop taking the medication immediately and consult a physician. Additionally, Sitagliptin can cause acute pancreatitis, which is an inflammation of the pancreas; therefore, any symptoms of pancreatitis such as abdominal pain, vomiting, or nausea should be reported to healthcare professionals immediately. Second, the Metformin component may rarely lead to a very serious metabolic disorder called lactic acidosis. Lactic acidosis occurs when lactic acid builds up excessively in the body, with symptoms such as fatigue, muscle pain, difficulty breathing, and abdominal pain; if any of these symptoms appear, emergency medical attention should be sought. This medication should not be used in patients with severely impaired kidney function, acute heart failure, severe infections, or liver dysfunction, and should be temporarily discontinued in cases of scheduled surgery or serious illness. While using this medication, regular blood tests and kidney function tests should be conducted, especially for elderly patients or those with impaired kidney function, who may require more frequent assessments. There is a risk of hypoglycemia with this medication, so those taking insulin or sulfonylureas should frequently check their blood sugar and be wary of symptoms of low blood sugar. Furthermore, situations that cause fluid loss, such as dehydration, diarrhea, or vomiting may lead to blood pressure reduction or electrolyte imbalance; hence, it is advisable to consult a healthcare professional in such circumstances. Genital infections or urinary tract infections may occur, and if related symptoms appear, immediate treatment should be sought. Additionally, severe fever or perineal pain could indicate serious infection, necessitating a visit to a medical institution. This medication must be swallowed whole without breaking, crushing, or chewing. Caution is needed when driving or operating machinery due to the risk of hypoglycemia. Finally, alcohol consumption can increase the risk of lactic acidosis, so it is advisable to avoid excessive drinking while on this medication.

Side effects

Severe hypersensitivity reaction, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, dyspepsia, abdominal pain, hyperglycemia, inadequately controlled diabetes, genital pruritus, vulvar pruritus, vaginal infection, weight loss, thirst, rash, urticaria, angioedema, decreased fluid volume, increased urination, dysuria, interstitial nephritis, increased serum lipids, increased serum creatinine, decreased glomerular filtration rate, vulvar dysplasia, vulvitis, balanitis, urinary tract infection, perineal necrosis, ketoacidosis, urosepsis, pyelonephritis, vascular stent stenosis, vascular stent thrombosis, diarrhea, nausea, gastric ulcer, colitis, vomiting, ischemic colitis, gastrointestinal bleeding, soft tissue infection, appendiceal abscess, appendicitis, meningitis, chronic otitis media, peritonsillar abscess, pneumonia, pulmonary tuberculosis, sepsis, subcutaneous abscess, adnexal-ovarian abscess, vestibular neuritis, acute pyelonephritis, headache, cerebral infarction, intracranial aneurysm, fever, vascular stent stenosis, vascular stent thrombosis, increased alanine aminotransferase, increased aspartate aminotransferase, ureteral calculi, acute kidney injury, cervical inflammation, hypernatremia, diabetes mellitus, diabetic foot, low back pain, glaucoma, pathological myopia, retinal detachment, retinal vein occlusion, macular retinal detachment, limb injury, road traffic accident, splenic injury, sternum fracture, angina, Prinzmetal's angina, coronary artery disease, deep vein thrombosis, benign neoplasm of the Bartter's dilatation, benign ovarian tumor, bladder cancer, gastric cancer, pancreatic carcinoma, rectal cancer, thyroid cancer, uterine leiomyoma, acute cholecystitis, autoimmune hepatitis, cholelithiasis, anxiety, depression, sleep disorders, otalgia, orthostatic dizziness, dizziness, anemia, lymphadenopathy, hypothyroidism, thyroid nodules, constipation, dyspepsia, vertigo, chest discomfort, chest pain, weakness, weight loss, vulvar pruritus, genital pruritus, dyslipidemia, hyperglycemia, low back pain, diabetic retinopathy, dry eyes, cough, dyspnea, unstable angina, hypertension, insomnia, taste disturbance, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, erythema, pruritus, urticaria, rash, severe joint pain accompanied by disability, blistering dermatitis herpetiformis, myalgia, limb pain, back pain, interstitial lung disease, thrombocytopenia, rhabdomyolysis, severe hypoglycemia, blistering dermatitis herpetiformis, blisters, maceration, acute renal failure, severe joint pain, recurrence of severe joint pain, hypoglycemia, decreased appetite, pica, vitamin B12 deficiency

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent exposure to air or moisture. It is advisable to maintain room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Light purple, double-convex oval-shaped controlled release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.